| Bioactivity | Antitumor agent-75 is a novel potent antitumor agent. Antitumor agent-75 has cytotoxic effects on cancer and normal human cell lines. Antitumor agent-75 shows a highly selective cytotoxic effect against human lung adenocarcinoma (cell line A549) when combined with Antitumor agent-74 (HY-151292), the IC50 value of 2.8 μM. Antitumor agent-75 can be used for the research of cancer[1]. |
| Target | IC50: 2.8 μM (A549 cells) |
| Invitro | Antitumor agent-75 (14da) shows a highly selective cytotoxic effect (combined with 13da, mrBIQ 13da/14da) against human lung adenocarcinoma (cell line A549) with an IC50 value of 2.8 μM[1].Antitumor agent-75 (1, 5, 25, 50, 100μM; 0-48 h) (mriBIQ 13da/14da) has the cytotoxic effect in A549 cells[1].Antitumor agent-75 (1, 2.5, and 5 μM; 12 h) (mriBIQ 13da/14da) has the mechanism of the cytotoxic effect on A549 cells may be associated with the stopping of the cell cycle in phase S and inhibition of DNA synthesis as well as with the induction of mithochondrial apoptosis[1].Antitumor agent-75 (1, 2.5 and 5 μM) increases the production of reactive oxygen species (ROS) and induces mitochondrial apoptosis in A549 cells. Cell Cytotoxicity Assay[1] Cell Line: |
| Name | Antitumor agent-75 |
| Formula | C26H23FN6 |
| Molar Mass | 438.50 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Vakhid A. Mamedov, et al. Synthesis of Morpholine‑, Piperidine‑, and N‑Substituted Piperazine-Coupled 2‑(Benzimidazol-2-yl)-3-arylquinoxalines as |